2nd Athenian Oncology Congress
2nd Athenian Oncology Congress
Improving cancer care by opening therapeutic avenues
22 – 23 Οκτωβρίου 2021
Δείτε το πρόγραμμα του συνεδρίου: ΠΡΟΓΡΑΜΜΑ ΣΥΝΕΔΡΙΟΥ
Διοργάνωση: Εταιρεία Μελέτης, Έρευνας και Θεραπείας της Μεταστατικής Νεοπλασματικής Νόσου
Σε συνεργασία με: Δ’ Ογκολογική Κλινική του Νοσοκομείου «Ερρίκος Ντυνάν»
Ημερομηνία Διεξαγωγής: 22 & 23 Οκτωβρίου 2021
Τόπος Διεξαγωγής: Athenaeum InterContinental
ΠΡΟΓΡΑΜΜΑ ΣΥΝΕΔΡΙΟΥ
Prof., MD – PhD, Chair Medical Oncology, Oncology Department –CHUV, Lausanne University. ESMO President 2020-2022, Scientific Coordinator, European Thoracic Oncology Platform (ETOP), Annals of Oncology Associate Editor
«The ESMO vision for 2025: One Oncology Community, Education for life, Accessible Cancer Care.»
Ass. Professor, Department of Investigational Cancer Therapeutics Division of Cancer Medicine, Executive Director, Medical Oncology Research, MD Anderson Cancer Network
«Targeting RET across the cancer spectrum.»
MD, PhD, MBA, Dr.hc.,Professor and Assoc. Director for Clinical Research Center for Thoracic Oncology
The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai
«The role of multiple target NGS in the treatment of cancer.»
MD PhD, Associate Professor, Clinical Director of Genitourinary Cancers Program, Division of
Oncology, Dept. of Medicine, University of Washington, Associate Member, Clinical
Research Division, Fred Hutchinson Cancer Research Center
«Opening new therapeutic avenues in bladder cancer.»
Consultant In Medical Oncology, Dep. of Medical Oncology, The Christie NHS Foundation Trust, Honorary Senior Lecturer, Division of Cancer Sciences, The University of Manchester
«Immunotherapy in the adjuvant setting of NSCLC.»
Medical Oncologist at Skåne University Hospital in Lund, Sweden & founder of Cancer News Service OncoAlert
«Fighting Cancer Through Social Media: The OncoAlert story.»
Head, Genitourinary Oncology Service, Meir Medical Center Fellow, Genitourinary Oncology Johns Hopkins Hospital
«How has Immunotherapy changed the first line aRCC treatment landscape: Forming the therapeutic algorithm with the entry of immunotherapeutic combinations in the first line of the advanced Renal Cell Carcinoma.»
MD, Associate Director of the Cancer Care Equity Program at the Dana-Farber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School
«Cancer Researchers and Clinicians should pay more attention to women.»
Senior Medical Oncologist Hôpital Riviera-Chablais, Vaud-Valais, Breast Unit Responsible and Disease Lead for Breast Cancer
«The global challenge of affordable cancer care.»
MD, PhD, Gustave Roussy, Head of Thoracic Cancer Group Department of Medical Oncology Thoracic Group
«Broadening the therapeutic spectrum of cancer: Exciting new targets. BRAF.»
Medical Oncology Department, Centro Integral, Oncología Clara Campal Barcelona-HM Delfos, Barcelona
«Broadening the therapeutic spectrum of cancer: Exciting new targets. NTRK.»
Medical Oncology, Santa Maria Della Misericordia Hospital, Azienda Ospedaliera, Perugia
«Broadening the therapeutic spectrum of cancer: Exciting new targets. KRAS.»
MD, Medical Oncologist, University Hospitals Leuven – Gasthuisberg, Laboratory of Experimental Oncology, KU Leuven, Belgium, Committee member of ESMO Young Oncologists Committee and Resilience Task Force
«Training Opportunities and career development in Europe: The ESMO perspective.»
Prof., EAPM Executive Director, Chair, ICGC ARGO Independent Advisory Committee at International Cancer Genome Chief Editor, Public Health Genomics
“Identifying the Steps Required to Implement Molecular Diagnostics in Personalized Cancer Care effectively at a National Level in Europe.»
Acting Director of Research at the IRCCS Fondazione Pascale Institute in Naples, Italy
«Oncology and biomarkers: Does Europe use their full potential?»
PhD, Biomedical Scientist Cancer Centre -Epidemiology and Public Health
«Practical guidance for Member States on implementing precision genomics in cancer care.»